Evidence map›Paper›PMID 31885584›Full record

ArticleJournal of oncology2019

Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials.

Bo Zhu, Changgui Kou, Wei Bai, Weiying Yu, Lili Zhang, Xiao Yu, Wen Xu, Huanhuan Wang, Ying Xin, Xin Jiang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Bo ZhuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, China.ORCID https://orcid.org/0000-0001-9469-1241
Changgui KouDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, China.ORCID https://orcid.org/0000-0001-9544-4066
Wei BaiDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, China.
Weiying YuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, China.
Lili ZhangDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, China.
Xiao YuDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, Jilin Province, China.
Wen XuDepartment of Social Medicine and Health Management, School of Public Health, Jilin University, Changchun, Jilin Province, China.
Huanhuan WangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, Jilin Province, China.
Ying XinDepartment of Pathology, School of Basic Medicine, Jilin University, Changchun, Jilin Province, China.ORCID https://orcid.org/0000-0001-7591-9423
Xin JiangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, Jilin Province, China.ORCID https://orcid.org/0000-0002-4613-7438
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe benefits of accelerated hyperfractionated radiotherapy (HART) and conventional fractionation radiotherapy (CFRT) in the treatment of head and neck cancer (HNC) remain controversial. In this study, we analyzed the therapeutic effects of these two treatment regimens to explore whether HART can improve the overall survival (OS) rate and locoregional control (LRC) rate in patients with HNC.

methodsThe PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for eligible studies. The OS rate and LRC rate were considered as the efficacy outcomes.

resultsTwelve qualified articles including a total of 2,935 patients were identified. HART had a significant beneficial effect on OS rate (HR = 0.80, 95% CI: 0.65-0.98). Compared with CFRT, HART demonstrated a significantly higher LRC rate (HR = 0.82, 95% CI: 0.71-0.96).

conclusionOur meta-analysis showed that HART can significantly improve OS and LRC compared with CFRT in patients with HNC.

Identifiers

PMID31885584
PMCPMC6914880
OpenAlexW2990984412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.